Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbamazepine + diazepam is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Carbamazepine is an anticonvulsant and mood-stabilizing agent primarily used to treat various types of seizures, trigeminal neuralgia (a type of nerve pain), and bipolar disorder. It works mainly by inhibiting voltage-gated sodium channels in neuronal membranes, stabilizing hyperexcited nerve cells and reducing synaptic transmission. Diazepam is a long-acting benzodiazepine used for its anxiolytic, muscle relaxant, anticonvulsant, and sedative properties. It acts as a positive allosteric modulator at the gamma-aminobutyric acid type A (GABA-A) receptor complex in the central nervous system, enhancing GABAergic inhibition[4][5][6][8]. The combination may be considered in clinical scenarios where both seizure control and acute anxiety or muscle spasm management are required; however, co-administration can result in pharmacokinetic interactions that may reduce the effectiveness of diazepam due to enzyme induction by carbamazepine[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbamazepine + diazepam.